For providers
Clinical evidence

Broader analytical validation. Greater confidence.

The next-generation Oncodetect® test is here, and it has a limit of detection 30x lower than our first-generation test1,2 while maintaining a >99% analytical specificity,3 resulting in deeper insights to inform personalized care.

With the power of MAESTRO technology, the next-generation Oncodetect test can:

Target

Identify thousands of patient-specific tumor variants4

Download MAESTRO (PDF)

Track

Scan thousands of tumor-specific mutations

Enrich

Enrich tumor variants by removing normal variants

Detect

Uncover low traces of ctDNA in the blood

Clinical validation studies

PARTNER TNBC study5

PARTNER is Abbott Cancer Diagnostics’ first MRD clinical study of triple-negative breast cancer (TNBC) patients using the next-generation Oncodetect test powered by MAESTRO.

  • The next-generation Oncodetect test demonstrated an approximately 3x stronger relationship with distant recurrence for distant recurrence-free interval and post-surgery ctDNA compared to the first-generation test.
  • The next generation Oncodetect test detected more samples at ultra-low ctDNA concentrations (10 ppm) relative to the first-generation test.
Ultrasensitive MRD tracking in esophageal cancer6

MRD analysis following curative intent treatment in patients with locally advanced esophageal cancer utilizing MAESTRO technology via the Oncodetect test, an ultrasensitive ctDNA assay.

  • Large percent of ctDNA-positive samples were in the ultrasensitive range (<100 ppm).7
  • Postoperative MRD was detected in 64% of patients who subsequently experienced recurrence.
  • With serial testing, next-generation Oncodetect test detected ctDNA in 100% of patients who ultimately experienced recurrence.
B-59 study7

As it pertains to the first-generation Oncodetect test, the B-59 study represents one of the largest clinical validations of a bespoke MRD assay using prospectively collected serial blood samples from patients with stage II–III TNBC.

  • The first-generation Oncodetect test demonstrated robust baseline ctDNA detection rate and significant prognostic value following surgery in early-stage TNBC patients.*
  • Detectable ctDNA after neoadjuvant therapy was associated with failure to achieve pathologic complete response (pCR).
  • Among patients with negative ctDNA results following surgery, 95% were free of metastatic disease at 3 years.
  • Post-surgical ctDNA positivity was associated with 30x higher risk of distant recurrence or breast cancer-specific death.

Next-generation MRD detection that works with the way you work

The next-generation Oncodetect test fits effortlessly into your workflow.

Supports multiple tests

Abbott Cancer Diagnostics can use a single tissue block to run both comprehensive genomic profiling and MRD testing.

Requires half the tissue

The Oncodetect test requires half the tissue compared to the most-used MRD test.8-14

Ordering a test for your patients is fast and easy

Order tests, access results, and receive updates through our Provider Hub.

Have questions?

Call us at +1 866-662-6897.